EQS Group-Media / 2020-05-28 / 19:15
*Media Release*
*Medacta Announces First Surgery Utilizing Mecta-C Stand Alone Anterior
Cervical Interbody Fusion Device and New Registrations*
_CASTEL SAN PIETRO_, _28 May 2020 _- Medacta announced today the first
surgery utilizing its recently FDA-cleared Mecta-C Stand Alone platform for
anterior cervical discectomy and fusion procedures (ACDF). After obtaining
the FDA clearance in March, Mecta-C Stand Alone has also obtained CE marking
and approval from Australia's Therapeutic Goods Administration (TGA).
The first surgery utilizing Mecta-C Stand Alone was performed by Heldo
Gomez, M.D., from Palm Beach Gardens, FL (USA). "The system's modular
implant design and simple to use instrumentation offers my patients a
dynamic solution for many anatomic variations," stated Dr. Gomez. "This
provides me with extreme confidence going into surgery that I will have the
right implant configuration for my patients available to meet their specific
needs."
Mecta-C Stand Alone is indicated for use from C2 to T1 in skeletally mature
patients suffering from degenerative disc disease. It incorporates the
benefits of an anterior plate with a versatile screw system, thus requiring
no additional fixation. The modular design is an important characteristic of
the Mecta-C Stand Alone system, allowing the surgeon to intraoperatively
select four plating options to best treat various patient needs and
anatomies. The Mecta-C Stand Alone anterior cervical interbody fusion
devices are offered in TiPEEK, Medacta's plasma-sprayed titanium coating
that provides an added value to improve stability and resistance to
migration.
Following the recent TGA approval and CE marking, Mecta-C Stand Alone will
be soon introduced in Australia and in several European countries, thus
providing global reach to the patient enriching suite of solutions for
treatment of numerous spine disorders.
For more information on Medacta Spine visit spine.medacta.com [1].
*Contact*
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch
*About Medacta*
Medacta is an international company specialized in the design and production
of innovative orthopaedic products and the development of accompanying
surgical techniques for joint replacement, spine surgery, and sports
medicine. Established in 1999 in Switzerland, Medacta's products and
surgical techniques are characterized by innovation. Medacta is a pioneer in
developing new offerings on the basis of minimally invasive surgical
techniques, in particular its Anterior Minimally Invasive Surgery (AMIS)
technique for hip replacements. Medacta has leveraged its orthopaedic
expertise and comprehensive understanding of the human body to develop the
sophisticated MySolutions technology, which offers surgeons highly
personalized pre-operative planning and implant placement methodologies by
creating advanced personalized kinematic models and 3D planning tools for
use in hip, knee, shoulder and spine procedures.
Issuer: Medacta Group SA
Key word(s): Research/Technology
End of Corporate News
Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1058243
End of News EQS Group Media
1058243 2020-05-28
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=d8972af999979a214b7de3d0ef17981b&application_id=1058243&site_id=vwd&application_name=news
(END) Dow Jones Newswires
May 28, 2020 13:15 ET (17:15 GMT)
